 15 PM / Updated 7 minutes ago BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab Reuters Staff 1 Min Read 
Jan 22 (Reuters) - Teva Pharmaceutical Industries Ltd : 
* TEVA ANNOUNCES TOP-LINE RESULTS FROM PHASE III STUDIES OF SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA 
* TEVA - PHASE III REGISTRATION STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB (110 MG) IN A PRE-FILLED SYRINGE DID NOT MEET PRIMARY ENDPOINT 
* TEVA - PHASE III CLAIM-SUPPORT STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH OCS-DEPENDENT ASTHMA DID NOT MEET PRIMARY ENDPOINT 
* TEVA -NO NEW SAFETY CONCERNS TO KNOWN SAFETY PROFILE, NO CASES OF ANAPHYLAXIS RELATED TO RESLIZUMAB IDENTIFIED IN REVIEW OF DATA FROM STUDIES Source text for Eikon: Further company coverage: